Advertisement

ThermoGenesis Holdings, Inc. THMO

Set alert

Price alert · THMO

All alert types
0.00 USD 0.00 0.00%

At close · Oct 29

0.0001 Day range 0.0001
0.0001 52-week range 0.0001
YTD
0.00%
1 year
0.00%
Open
0.0001
Prev close
0.0001
Mkt cap
1.58K
Vol
100
Avg vol
122
EPS
-5.14
P/E
0.00
Div yield
0.00%
More statistics
Low
0.0001
High
0.0001
Forward P/E
0.65
Beta
2.29
Short ratio
1.44
Inst. own
1.13%
Dividend
0.00
Ex-div date
Earnings
Dec 23, 2024
50-d avg
0.4714
200-d avg
0.7407
1y target
0.00

3M chart

Chart tools
Interval

Key statistics

Market cap
2.06M
Enterprise value
5.36M
Trailing P/E
0.00
Forward P/E
0.65
PEG ratio
0.00
Price / sales
0.21
Price / book
1.06
EPS (TTM)
-3.98
Beta
2.29
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-153.43%
Revenue (TTM)
9.61M
Revenue growth
6.40%
Free cash flow
-67.88K
Total cash
1.18M
Total debt
7.57M
Return on equity
-801.94%
Shares outstanding
15.85M
Short % of float
0.30%
50-day average
0.4714
200-day average
0.7407

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Dec 23, 2024

Expected Dec 23, 2024. Consensus EPS estimate 0.02.

Earnings history

Financials — quick view

All financials
THMO Revenue — quarterly 2.74M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
THMO Net income — quarterly -1.86M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
THMO EPS — quarterly -0.46
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024

Earnings

THMO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 23, 2024Sep 1, 20240.02———
Oct 3, 2024Jun 1, 20240.02———
May 17, 2024Mar 1, 20240.01-0.46-0.47-4,700.00%
Apr 15, 2024Dec 1, 20230.00-2.33——
Nov 13, 2023Sep 1, 2023-0.21-1.44-1.23-585.71%
Aug 10, 2023Jun 1, 20230.01-0.91-0.92-9,200.00%

Upgrades / downgrades

THMO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 10, 2023HC Wainwright & Co.reitBuyBuy
May 15, 2023HC Wainwright & Co.reitBuyBuy
Apr 2, 2023HC Wainwright & Co.reit—Buy

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on THMO — it syncs with the Stock Master app.

Insider holders

THMO insider holders
InsiderRelationLatest transactionDateShares held
BOYALIFE HONG KONG LTD.Beneficial Owner of more than 10% of a Class of SecurityPurchaseDec 25, 20166,838,240
BRUCH MICHAELChief Financial OfficerStock Award(Grant)Jul 25, 201630,688
CAUBLE JEFFERYOfficerStock Award(Grant)Jun 29, 20175,240
ELLNER KIMBERLY KAYOfficerStock Award(Grant)Jul 25, 201620,818
LIU VIVIAN HChief Operating OfficerStock Award(Grant)Feb 23, 201725,000
MOORE CRAIG WDirectorStock Award(Grant)Jun 30, 20167,788

Institution ownership

THMO institution ownership
Holder% heldSharesValueReported
Raymond James & Associates, Inc.2.01%50,00464.00KJun 29, 2023
Vanguard Group Inc1.43%35,41945.34KJun 29, 2023
Citadel Advisors Llc0.54%13,42117.18KJun 29, 2023
Morgan Stanley0.37%9,29411.90KJun 29, 2023
Tower Research Capital LLC (TRC)0.23%5,7567.37KJun 29, 2023
Blackrock Inc.0.06%1,4931.91KJun 29, 2023

Fund ownership

THMO fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund1.43%35,41945.34KJun 29, 2023
Fidelity Series Total Market Index Fund0.06%1,5382.00KMay 30, 2023
Fidelity Extended Market Index Fund0.03%707919May 30, 2023
Fidelity NASDAQ Composite Index Fund0.01%146189May 30, 2023
Advertisement